our patients.

So what we're dealing here is gastroesophageal cancer, which, of course, is a systemic disease in nature.

And the risk of cancer recurrence is substantial.

Of course, both local and distant recurrences are an issue.

But in the age of modern surgery in a tertiary cancer center, really most patients suffer and die from systemic disease recurrence.

And so what we would argue today, again, is that in an area of expertise where you have a specialty center, excellent access to surgery, really one form of local therapy is enough.

Surgery and radiation is a secondary approach, and we don't need it because it does not improve survival.

And there's a couple of people that are not sure.

So what we're dealing

here is gastroesophageal cancer, which, of course, is a systemic disease in nature.

And the risk of cancer recurrence is substantial.

Of course, both local and distant recurrences are an issue.

But in the age of modern surgery in a tertiary cancer center, really most patients suffer and die from systemic disease recurrence.

And so what we would argue today, again, is that in an area of expertise where you have a specialty center, excellent access to surgery, really one form of local therapy is enough.

Surgery and radiation is a secondary approach, and we don't need it because it does not improve survival.

and there's some folks who want to switch to adjuvant monotherapy drivalumab, and there's a couple of people that are not sure.

So what we're dealing

here is gastroesophageal cancer, which, of course, is a systemic disease in nature.

And the risk of cancer recurrence is substantial.

Of course, both local and distant recurrences are an issue.

But in the age of modern surgery in a tertiary cancer center, really most patients suffer and die from systemic disease recurrence.

And so what we would argue today, again, is that in an area of expertise where you have a specialty center, excellent access to surgery, really one form of local therapy is enough.

Surgery and radiation is a secondary approach, and we don't need it because it does not improve survival.

and there's some folks who want to switch to adjuvant monotherapy drivalumab, and there's a couple of people that are not sure.